---
title: "EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288254024.md"
description: "EUDA Health Holdings Limited has regained compliance with Nasdaq's continued listing requirements. This follows a notification received on April 23, 2026, regarding a deficiency in the Minimum Market Value of Listed Securities (MVLS) for 32 consecutive business days. The company successfully addressed the MVLS requirement stipulated by Nasdaq Listing Rule 5550(b)(2)."
datetime: "2026-06-01T10:01:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288254024.md)
  - [en](https://longbridge.com/en/news/288254024.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288254024.md)
generator: "portal-rs"
---

# EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Singapore, June 01, 2026 - EUDA Health Holdings Limited (referred to as "EUDA" and the "Company"), a non-invasive healthcare provider based in Singapore focusing on Singapore, Malaysia, and China, recently received a written notice (referred to as the "MVLS Notice") from the Listing Qualifications Department of The Nasdaq Stock Market on April 23, 2026. The notice highlighted that the Company had not maintained a Minimum Market Value of Listed Securities (MVLS) of $35 million for the past 32 consecutive business days, as stipulated by the Nasdaq Listing Rule 5550(b)(2).

### Related Stocks

- [EUDA.US](https://longbridge.com/en/quote/EUDA.US.md)
- [EUDAW.US](https://longbridge.com/en/quote/EUDAW.US.md)

## Related News & Research

- [EUDA Health signs MOU with GO POSB, SIIT to develop off-the-shelf iPSC cell therapies](https://longbridge.com/en/news/294340008.md)
- [EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask | EUDA Stock News](https://longbridge.com/en/news/288252101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**